Spartalizumab
- Generic Name
- Spartalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1935694-88-4
- Unique Ingredient Identifier
- QOG25L6Z8Z
- Background
Spartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
- Conditions
- Oesophageal AdenocarcinomaGastric Adenocarcinoma
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 90
- Registration Number
- NCT05135845
- Locations
- 🇫🇷
Centre François Leclerc, Dijon, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Universitaire du Cancer, Toulouse, France
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04895748
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸Memorial Sloane Ketterin Cancer Ctr, New York, New York, United States
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
- Conditions
- Nasopharyngeal CarcinomaMicrosatellite Stable Colorectal CancerCarcinoma, Non-Small-Cell LungMelanomaTriple Negative Breast Cancer
- Interventions
- Drug: DKY709Drug: PDR001
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT03891953
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 573
- Registration Number
- NCT02967692
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸UC Irvine Medical Center, Orange, California, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.